RT Journal Article
SR Electronic
T1 Sex-Related Differences in Eicosanoid Levels in Chronic Thromboembolic Pulmonary Hypertension
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.20.22274927
DO 10.1101/2022.05.20.22274927
A1 Mona Alotaibi
A1 Timothy Fernandes
A1 Amber B. Tang
A1 Gino Alberto Magalang
A1 Jeramie D. Watrous
A1 Tao Long
A1 Victor Pretorius
A1 Michael Madani
A1 Nick H. Kim
A1 Mohit Jain
A1 Susan Cheng
YR 2022
UL http://medrxiv.org/content/early/2022/05/21/2022.05.20.22274927.abstract
AB A sex paradox is seen in pulmonary arterial hypertension (PAH) whereby female sex is a risk factor for development of the disease but male sex is often associated with poorer outcomes. Although data are limited regarding the potential molecular mechanisms underlying sex-specific variations in PAH including its various subtypes, there is emerging evidence regarding the potential role of sex differences in pathways governing the balance between underlying inflammatory and vasoactive mechanisms. Chronic thromboembolic pulmonary hypertension (CTEPH) is a subtype of pulmonary hypertension that is classically characterized as a procoagulant state and yet also involving some degree of proinflammatory activity. Therefore, we sought to determine whether eicosanoid mediators, endogenous lipid signaling molecules that have been implicated in a range of inflammatory and vasoactive responses, vary by sex in patients with CTEPH. We studied 287 patients (43.5% female) with confirmed CTEPH from a single center and assayed plasma samples using liquid chromatography – mass spectrometry to profile 500 eicosanoid analytes. We found significant sex-specific variations in eicosanoid profiles after adjusting for age and BMI, with males demonstrating a predominance of inflammatory-pathway related eicosanoids. Sex-specific variation in eicosanoid pathway related mechanisms may underlie sexual dimorphism in CTEPH outcomes.Competing Interest StatementNone of the authors have any potential conflicts of interest relative to the study. NHK has served as consultant for Bayer, Janssen, Merck, United Therapeutics and has received lecture fees for Bayer, Janssen. NHK has received research support from Acceleron, Eiger, Gossamer Bio, Lung Biotechnology, SoniVie. A.M.B. served as a consultant to Biogen. Funding StatementThis work was supported in part by National Institutes of Health (NIH) grants S10OD020025, R01ES027595, K01DK116917, R01HL131532, R01HL151828, U54AG065141, and a pulmonary hypertension PHAB award from Bayer.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of California San Diego gave ethical approval of this work and all patients signed informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for de-identified data may be directed to the corresponding authors (MJ, SC) and will be reviewed by the Office of Research Administration at UCSD prior to issuance of data sharing agreements. Data limitations are designed to ensure patient and participant confidentiality.BMIBody mass indexCTEPHChronic thromboembolic pulmonary hypertensionPAHPulmonary arterial hypertensionLC-MSLiquid chromatography - mass spectrometrymRAPMean right atrial pressurePAHPulmonary arterial hypertensionPVRPulmonary vascular resistanceRHCRight heart catheterization6MWD6-minute walk distance